help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rawadi, G.
Right arrow Articles by Baron, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rawadi, G.
Right arrow Articles by Baron, R.
Endocrinology Vol. 142, No. 11 4673-4682
Copyright © 2001 by The Endocrine Society

ARTICLES

1-(5-Oxohexyl)-3,7-Dimethylxanthine, a Phosphodiesterase Inhibitor, Activates MAPK Cascades and Promotes Osteoblast Differentiation by a Mechanism Independent of PKA Activation (Pentoxyfilline Promotes Osteoblast Differentiation)

Georges Rawadi, Caroline Ferrer, Sylviane Spinella-Jaegle, Sergio Roman-Roman, Yasmina Bouali and Roland Baron

Bone Diseases Group, Aventis (G.R., C.F., S.S.-J., S.R.-R., Y.B., R.B.), 93230 Romainville, France; and Departments of Cell Biology and Orthopedics, Yale University School of Medicine (R.B.), New Haven, Connecticut 06510

Address all correspondence and requests for reprints to: Dr. Georges Rawadi, Bone Disease Group, Aventis, 102 route de Noisy, 93230 Romainville Cedex, France. E-mail: georges.rawadi{at}aventis.com


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have investigated the effect of 1-(5-oxohexyl)-3,7-dimethylxanthine or pentoxifylline (PeTx), a nonselective phosphodiesterase inhibitor, on osteoblastic differentiation in vitro by using two mesenchymal cell lines, C3H10T1/2 and C2C12, which are able to acquire the osteoblastic phenotype in the presence of bone morphogenetic protein-2 (BMP-2). PeTx induced the osteoblastic markers, osteocalcin and Osf2/Cbfa1, in C3H10T1/2 and C2C12 cells and enhanced BMP-2-induced expression of osteocalcin, Osf2/Cbfa1, and alkaline phosphatase. This activity was partially attributed to the fact that PeTx is able to enhance BMP-2-induced Smad1 transcriptional activity. Although PeTx clearly stimulates PKA in these cells, neither pretreatment of cells with the PKA inhibitor H89 nor transfection with the specific PKA inhibitor PKI prevented the induction or enhancement of osteoblast markers by PeTx, demonstrating that these effects were independent of PKA activation. On the other hand, PeTx induced the activation of ERK1/2 and p38 kinase pathways independently of the activation of PKA. Selective inhibitors of these MAPK cascades prevented the induction of osteoblastic markers in cells treated with PeTx, suggesting that the activation of these two pathways plays a role in the effect of PeTx on osteoblastic differentiation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
OSTEOPOROSIS AND OTHER diseases of bone loss are a major public health problem. Despite recent successes with drugs that inhibit bone resorption, notably bisphosphonates, there is a clear therapeutic need for bone anabolic molecules (i.e. compounds able to increase bone formation), especially in the case of patients who have already suffered a substantial bone loss (1). PTH and PGE2 stimulate bone formation in experimental animals and in humans (2, 3). Importantly, the receptors for these two molecules are coupled to a variety of G proteins that activate their specific second messenger signaling cascades: cAMP, calcium, and IP3 (4, 5, 6). Several studies strongly suggest that the anabolic effects of these two molecules are mainly mediated by cAMP, and it has been hypothesized that molecules increasing cAMP could mimic the anabolic effects of PTH and PGE2 on bone.

Different members of the cyclic nucleotide phosphodiesterase (PDEs) family are enzymes that hydrolyze cAMP and cGMP and therefore play a crucial role in modulating cAMP levels (7). In recent years a number of inhibitors displaying various degrees of selectivity for the different types of PDEs have been developed (8). Interestingly, some PDE inhibitors have been reported to stimulate osteoblastic differentiation and inhibit osteoclastic differentiation in vitro (9, 10). Very recently, Kinoshita et al. (11) demonstrated that the PDE inhibitors 1-(5-oxohexyl)-3,7-dimethylxanthine [known as pentoxifylline (PeTx)] and rolipram increase bone mass mainly by promoting bone formation in normal mice. Furthermore, PDE inhibitors have been shown to exert therapeutic effects in different experimental osteopenia models (10, 12, 13). Although these effects might be linked to the increase in cAMP levels induced by PDE inhibitors, little is known about the precise mechanisms by which PDE inhibitors stimulate bone cells.

In the present study we have investigated the effect of 1-(5-oxohexyl)-3,7-dimethylxanthine or PeTx, a nonselective PDEs inhibitor, on osteoblast differentiation using two murine pluripotent mesenchymal cell lines, C3H10T1/2 and C2C12, that are able to differentiate in osteoblasts when treated with bone morphogenetic protein-2 (BMP-2). The effect of the PDE inhibitor in the presence or absence of BMP-2 was assessed by measuring the osteoblast-specific markers alkaline phosphatase (ALP), osteocalcin (OC), and Osf2/Cbfa1. In addition, we evaluated the involvement of MAPK, ERK1/2, and p38 signaling pathways in the observed effects.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents and antibodies
Myelin basic protein and PeTx were obtained from Sigma (St. Louis, MO). SB203580, PD98059, and H89 were obtained from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA). Anti-ERK (K23), anti-p38 (C20), and protein A-Sepharose beads were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). p38/RK/Mpk2 assay kit was available through Upstate Biotechnology, Inc. (Lake Placid, NY). [{gamma}-32P]ATP (3000 Ci/mmol) was commercially available from Amersham Pharmacia Biotech (Arlington Heights, IL). PKA PepTag and the dual luciferase assay system were purchased from Promega Corp. (Madison, WI). Recombinant BMP-2 was purified from CHO cells stably transfected with a plasmid expression vector for human BMP-2.

Cell culture
C3H10T1/2, obtained from American Type Culture Collection (Manassas, VA), and MC3T3-E1, provided by Dr. R. Franceschi (University of Michigan, Ann Arbor, MI), cell lines were cultured (5% CO2 at 37 C) in {alpha}MEM supplemented with 10% heat-inactivated FCS and antibiotics (100 U/ml penicillin-G and 100 µg/ml streptomycin). The mouse myoblast cell line C2C12 was provided by Dr. Gerard Karsenty (Baylor College of Medicine, Houston, TX). C2C12 cells were maintained (5% CO2 at 37 C) in DMEM containing 15% FBS and antibiotics (100 U/ml penicillin-G and 100 µg/ml streptomycin). For treatment, the cells were plated in 24-well plates at 2 x 104 cells/cm2. Twenty-four hours later, the growth medium was replaced with a similar medium containing 2% FBS, then cells were stimulated with the indicated compound for the indicated time period.

Gene expression analysis by real-time TaqMan PCR
Murine OC and Osf2/Cbfa1 mRNA expression was determined by RT, followed by real-time TaqMan PCR analysis as previously described (14). RT reactions were carried out using 500 ng total RNA with the following conditions: 42 C for 60 min, 95 C for 5 min, and 4 C for 5 min. RT product was diluted three times in sterile bidistilled water, and 5 µl were used to perform TaqMan PCR. ALP TaqMan PCR was carried our in a 25-µl final volume containing: 1x TaqMan EZ buffer, 5 mM Mn(Oac)2, 200 µM dA/dC/dG/deoxy-UTP, 0.625 U AmpliTaq Gold, 300 nM each of murine OC primer (forward and reverse), 40 nM each of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reverse and forward primers, and 200 nM each of GAPDH and OC TaqMan probes. Cycling conditions were 95 C for 15 sec and 60 C for 1 min for 40 cycles. Real-time TaqMan PCR was performed in an ABI PRISM 7700 sequence detector (PE Applied Biosystems, Foster City, CA). Conditions for Osf2 TaqMan PCR were exactly the same as those used for the OC reaction, except that OC primers and probe were replaced by Osf2 ones. All PCR reactions were performed in duplicate, and OC or Osf2 signal was normalized to GAPDH signal in the same reaction.

Determination of ALP activity
At the indicated time of treatment cells were lysed at 37 C in lysis buffer containing 1 mM MgCl2 and 0.2% Nonidet P-40. ALP activity was determined using the ALP Opt kit (Roche, Mannheim, Germany) and was normalized to the protein concentration determined by the bicinchoninic acid protein assay kit (Pierce Chemical Co., Rockford, IL).

Measurement of MAPK and PKA activities
Cells were stimulated with PeTx for appropriate time intervals and washed twice with ice-cold PBS containing 1 mM Na3VO4. One hundred microliters of the following lysis buffer were added to cells: 20 mM 3-(N-morpholino)propanesulfonic acid) (pH 7.2), 5 mM EDTA, 1% (vol/vol) Nonidet P-40, 1 mM dithiothreitol, 75 mM ß-glycerol phosphate, 1 mM Na3VO4, and protease inhibitor mixture (Sigma). Lysis was performed at 4 C for 20 min with continuous shaking. Cell lysates were cleared by centrifugation, then stored at -80 C. The protein concentration in cell lysates was determined by micro-bicinchoninic acid assay (Pierce Chemical Co.).

ERK1/2 and p38 were immunoprecipitated by incubating 250 µg cell lysates with 2 µg anti-ERK1-CT Ab or with 10 µg anti-p38 Ab at 4 C for 4 h with continuous rotation. Then, 30 µl protein A-Sepharose were added, and the incubation was extended for 2 more h. The mixtures were centrifuged (7000 x g for 2 min at room temperature), and protein A-Sepharose beads were washed three times with buffer B [12.25 mM 3-(N-morpholino)propanesulfonic acid (pH 7.2), 0.5 mM EGTA, 1% (vol/vol) Nonidet P-40, 1 mM dithiothreitol, 12.5 mM ß-glycerol phosphate, and 7.5 mM MgCl2] containing 250 mM NaCl. The beads were resuspended in 50 ml buffer B containing 10 mM MgCl2 and 1 mM MnCl2 for phosphotransferase assays. For measuring ERK activity, 10 mg myelin basic protein in the presence of 50 µM [{gamma}-32P]ATP were added to ERK1/2 immunoprecipitates. The reaction was conducted at 30 C for 30 min, then terminated by adding SDS sample buffer to a 1x final concentration. Samples were analyzed by SDS-PAGE using 12% gels. Gels were fixed in 10% acetic acid and 50% methanol, then embedded in cellophane sheets and dried. Gels were exposed to a phospho-screen and quantitatively assessed by mean of QuantityOne software (Bio-Rad Laboratories, Inc., Hercules, CA). p38 activation in immunoprecipitates was determined by measuring its phosphotransferase activity toward peptide substrate using the p38/MpK2 detection kit. p38 activity was expressed as [32P]TP counts per min. PKA activity in cell lysates was determined y using the PKA PepTag kit (Promega Corp.) following the manufacturer’s instruction.

Plasmids and transfections
pGal4Smad1 and the Gal4-dependent luciferase construct, pG15E1b-luc, were provided by Dr. A. Atfi (INSERM, Hôpital Saint Antoine, Paris, France). pRSV-PKI and pRSV-PKImut were provided by Dr. R. A. Maurer (Oregon Health Science University, Portland, OR). The murine OC promotes (mOG2), the luciferase reporter (pmOG2/luc), and mOG2 minimal promoter-luciferase reporter construct (p147/luc) (15) were provided by Dr. G. Karsenty. Cells were transiently transfected with luciferase reporter constructs with or without other expression plasmid (total, 1 µg DNA) using DNA-lipid complex Fugene 6 (Roche) according to the manufacturer’s protocol. To assess transfection efficacy and normalize firefly luciferase signal, 20 ng pRL-TK (Promega Corp.), which encodes a Renilla luciferase gene downstream of a minimal herpes simplex virus-thymidine kinase promoter, was systematically added to the transfection mix. Eighteen hours later, cells were washed and cultivated with fresh medium containing 2% FBS, then stimulated with PeTx for 24 h. Luciferase assays were performed with the Dual Luciferase Assay Kit (Promega Corp.) according to the manufacturer’s instructions. Ten microliters of cell lysate were assayed first for firefly luciferase and then for Renilla luciferase activity. Firefly luciferase activity was normalized to Renilla luciferase activity.

Statistical analysis
All experimental data presented were obtained from two independent experiments, each performed in triplicate, and results are expressed as the mean ± SD. Comparisons between treatments were performed by t test. P < 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
PeTx enhances osteoblast differentiation
To determine whether PeTx affects osteoblast differentiation, we investigated the effect of PeTx on the mesenchymal cell line C3H10T1/2 and the pluripotent myoblast cell line C2C12. Treatment with BMP-2 induces in these two cell lines the expression of osteoblast markers, including ALP, OC, and Osf2/Cbfa1 (16). We therefore tested whether PeTx was able to affect the expression of osteoblast markers. C3H10T1/2 and C2C12 cells were treated with increasing concentrations of PeTx in the presence or absence of BMP-2 (100 ng/ml). After 3 d of treatment, ALP induction was determined by measuring its activity in cell lysates. PeTx alone had no effect on ALP activity in C3H10T1/2 cells (Fig. 1AGo), but enhanced BMP-induced ALP activity in a dose-dependent manner (Fig. 1AGo). These results were confirmed by the measurement of ALP mRNA using real-time TaqMan PCR (data not shown). Similar data were obtained with C2C12 cells (data not shown).



View larger version (28K):
[in this window]
[in a new window]
  		Figure 1. PeTx enhances BMP-2-induced ALP expression in C3H10T1/2 cells by increasing Smad1 transcriptional activity. A, C3H10T1/2 cells were treated with BMP-2 alone (100 ng/ml), PeTx alone at the indicated concentration, or BMP-2 and PeTx. Cells were treated for 3 d, and ALP activity was determined by enzymatic assay in C3H10T1/2 cell lysates. D, C3H10T1/2 cells were transiently cotransfected with Gal4Smad1 expression vector and Gal4-binding element/luciferase reporter construct. Eighteen hours after transfection, medium was replaced by 2% FCS medium and cotransfected cells were stimulated with BMP-2 (100 ng/ml), PeTx (1.8 mM), or both. After 24-h stimulation, luciferase activity was measured in cell lysates and normalized to Renilla luciferase signal. Data represent the mean ± SD of a representative experiment. *, P < 0.05, cells treated with BMP-2 compared with untreated cells. **, P < 0.05, cells treated with BMP-2/PeTx compared with BMP-2-treated cells.

 
Smad proteins are transcriptional comodulators critical for transmitting BMP signals from the cell surface to the nucleus. Phosphorylation and activation of Smad1 have been demonstrated to be necessary for the induction of ALP gene expression and activity by BMP-2 (17, 18). We therefore investigated whether the enhancement of BMP-2-induced ALP by PeTx could be due to a modulation of the transcriptional activity of Smad1. C3H10T1/2 cells were cotransfected with a plasmid containing a fusion of the Gal4 DNA-binding domain and Smad1 and a Gal4-dependent luciferase reporter construct, and cells were treated with BMP-2 in the presence or absence of PeTx. The data presented in Fig. 1BGo clearly show that whereas PeTx alone did not affect Smad1 activity, it strongly enhanced BMP-2-induced Smad1 transcriptional activity.

We then investigated the effect of PeTx on OC mRNA transcription in C3H10T1/2 and C2C12 cells. Interestingly, and in contrast with ALP, PeTx alone induced OC mRNA transcription in addition to enhancing BMP-2-induced OC transcripts (Fig. 2AGo). The effect of PeTx on OC was further addressed using pmOG2/luc and p147/luc, two reporter plasmids containing, respectively, the wild-type mouse OC promoter and the minimal OC promoter (-147/+13) (15). C3H10T1/2 cells were transiently transfected with p147/luc, then treated with PeTx. As expected, PeTx treatment induced about 3-fold the expression of both versions of the luciferase-OC reporter genes (Fig. 2BGo).



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. PeTx induces OC gene expression in C3H10T1/2 and C2C12 cells. A, C3H10T1/2 or C2C12 cells were treated for 3 d with BMP-2 (100 ng/ml), PeTx (1.8 mM), or both. RNA was then extracted, and the expression level of OC was analyzed by real-time TaqMan PCR, normalized to GAPDH expression, and presented as the expression level relative to that in control untreated cells. B, C3H10T1/2 cells were transiently transfected with pmOG2/luc or p147/luc reporter constructs. The culture medium of transfected cells was changed to 2% FCS 18 h after transfection, then cells were stimulated with PeTx (1.8 mM) for an additional 24 h. Luciferase activity was measured in cell lysates and normalized to Renilla luciferase signal. Data represent the mean ± SD of a representative experiment. *, P < 0.001 cells treated with BMP-2 or PeTx compared with untreated control cells. **, P < 0.05 cells treated with BMP-2/PeTx compared with BMP-2-treated cells.

 
Osf2/Cbfa1 is the earliest and most specific marker of osteoblast differentiation known. We therefore also tested whether PeTx regulated osf2/Cbfa1 expression. The data presented in Fig. 3AGo clearly show that PeTx alone induced the expression of this osteoblast-specific marker in both C3H10T1/2 and C2C12 cell lines and enhanced BMP-2 induced Osf2/Cbfa1 expression. These findings were further confirmed using a reporter construct containing a luciferase gene driven by the human Osf2/Cbfa1 promoter, phOsf2/luc. As described in Fig. 3BGo, PeTx was able to induce a 3-fold increase in luciferase activity in cells transiently transfected with pOsf2/luc.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. PeTx stimulates Osf2/Cbfa1 gene expression in C3H10T1/2 and C2C12 cells. A, C3H10T1/2 or C2C12 cells were treated for 3 d with BMP-2 (100 ng/ml), PeTx (1.8 mM), or both. RNA was then extracted, and the expression level of Osf2/Cbfa1 was analyzed by real-time TaqMan PCR, normalized to GAPDH expression, and presented as the expression level relative to that in control untreated cells. B, C3H10T1/2 cells were transiently transfected with pOsf2/luc reporter construct. The culture medium of transfected cells was changed to 2% FCS 18 h after transfection, then cells were stimulated with PeTx (1.8 mM) for an additional 24 h. Luciferase activity was measured in cell lysates and normalized to Renilla luciferase signal. Data represent the mean ± SD of a representative experiment. *, P < 0.001 cells treated with BMP-2 or PeTx compared with untreated control cells. **, P < 0.05 cells treated with BMP-2/PeTx compared with BMP-2-treated cells.

 
The data obtained for ALP, OC, and Osf2/Cbfa1 expression strongly suggested that PeTx is able to induce osteoblast commitment and enhance the activity of BMP-2. We then investigated the mechanism by which PeTx could influence osteoblastic differentiation.

PeTx activity is independent of PKA activation
It is well established that PDEs inhibitors increase intracellular cAMP levels, which, in turn, activate PKA. In agreement with that observation, a strong increase in cAMP in C3H10T1/2 and C2C12 cells could be detected after treatment with PeTx (data not shown). In addition and as shown in Fig. 4AGo, a 15-min treatment with PeTx induced a significant activation of PKA. Similar data were obtained using C2C12 cells (data not shown). To verify the involvement of PKA in the observed PeTx activity, an inhibitor of PKA, H89, was used. Cells were pretreated for 1 h with increasing concentrations of H89 and then stimulated for 15 min with PeTx (1.8 mM) before measuring PKA in cell lysates. A significant inhibition of PeTx-induced PKA activation was already observed at 1 µM H89 (Fig. 4AGo) and 2–5 µM H89 completely abolished PKA activation without any detectable effect on cell viability (data not shown). C3H10T1/2 cells were preincubated for 1 h with 2 µM H89 before stimulation with PeTx and BMP-2, and ALP activity was determined 3 d after stimulation. H89, at a concentration that blocked PKA activation, had no effect on the enhancement of ALP activity induced by BMP-2/PeTx (Fig. 4BGo). Furthermore, H89 (at 2 µM) pretreatment of C3H10T1/2 cells transfected with p147/luc or pOsf2/luc constructs had no effect on the luciferase induction by PeTx (Fig. 4CGo). To further investigate the involvement of PKA in PeTx activity, C3H10T1/2 cells were cotransfected with a plasmid overexpressing PKI (pRSV-PKI), a specific PKA inhibitor, and the p147/luc construct, and then stimulated with PeTx. Control experiments were performed using a mutated form of PKI, pRSV-PKIm. PKI overexpression did not show any inhibitory effect on luciferase induction in response to PeTx stimulation (Fig. 4DGo). Similar results were obtained in C2C12 cells (data not shown). In conclusion, these data clearly demonstrate that PeTx-induced PKA activation is not involved in the enhancement by PeTx of BMP-2-induced ALP production or in the increase in OC and Osf2/Cbfa1 expression.



View larger version (39K):
[in this window]
[in a new window]
  		Figure 4. PeTx enhances BMP-2-stimulated ALP and induces OC and Osf2/Cbfa1 expression by a mechanism independent of PKA activation. A, C3H10T1/2 cells were treated for 15 min with PeTx (1.8 mM), alone or in the presence of H89 at increasing concentrations. PKA activity was determined in cell lysates as described in Materials and Methods. The gel was scanned, and the PKA induction was estimated as the ratio of phosphopeptide in treated vs. nontreated cells. The experiment was repeated three times, and a representative gel is herein shown. B, C3H10T1/2 cells were pretreated with H89 (2 µM) or left untreated for 1 h before stimulation with BMP-2 (100 ng/ml) or BMP-2 and PeTx (1.8 mM). After 3 d ALP activity was determined in cell lysates. C, C3H10T1/2 cells were transiently transfected with p147/luc or pOsf2/luc reporter constructs. The culture medium of transfected cells was changed to 2% FCS 18 h after transfection, then cells were preincubated with H89 (2 µM) for 1 h before challenge with PeTx (1.8 mM) for an additional 24 h. Luciferase activity was measured in cell lysates and normalized to Renilla luciferase signal. D, C3H10T1/2 cells were transiently cotransfected with p147/luc or pOsf2/luc reporter constructs and pRSV-PKI or pRSV-PKIm expression vectors. The culture medium of transfected cells was changed to 2% FCS 18 h after transfection then, cells were stimulated with PeTx (1.8 mM) for an additional 24 h. Luciferase activity was measured in cell lysates and normalized to Renilla luciferase signal. Data represent the mean ± SD of a representative experiment. *, P < 0.001, cells treated with BMP-2 or PeTx compared with untreated control cells. **, P < 0.001, cells treated with BMP-2/PeTx compared with BMP-2-treated cells.

 
PeTx activates ERK1/2 and p38
MAPKs are important mediators involved in the intracellular network of signal transduction. To date, several MAPKs have been reported to be involved in osteoblastogenesis, including ERK1/2 and p38 (19, 20, 21). We therefore investigated whether the effects of PeTx on osteoblasts could be explained by an activation of ERK1/2 and/or p38 in C3H10T1/2 and C21C2 cells. Both cell lines were treated with PeTx for different time intervals, and cell lysates were tested for ERK1/2 and p38 activation by measuring their respective phosphotransferase activities. Activation of ERK1/2 was determined by measuring the phosphorylation of myelin basic protein after immunoprecipitation of lysates with an anti-ERK Ab. ERK1/2 was strongly activated in both C3H10T1/2 and C2C12 cells treated with PeTx (Fig. 5AGo). In C3H10T1/2 cells, maximum activity was detected after 20-min stimulation, then it rapidly decreased to control levels, while in C2C12 cells, maximum activity was observed at 30 min and remained high up to 60 min (Fig. 5AGo).



View larger version (29K):
[in this window]
[in a new window]
  		Figure 5. PeTx stimulates ERK and p38 pathways in mesenchymal cells. C3H10T1/2 and C2C12 cells were treated with PeTx for different periods (4, 10, 20, 30, and 60 min), and p38 or ERK1/2 were immunoprecipitated from cell lysates using anti-p38 or anti-ERK antibodies as described in Materials and Methods. ERK1/2 (A) or p38 (B) activation was quantified in immunoprecipitates using p38/RK/Mpk2 or p42/44MAPK detection kits, respectively. C and D, Cells were preincubated or not with H89 (2 µM) for 1 h before treatment with PeTx. Then, p38 and ERK1/2 activation was determined in cell lysates after, respectively, 10 or 20 min of treatment. Data represent the mean ± SD of a representative experiment (P < 0.05).

 
p38 activation was measured after immunoprecipitation with an anti-p38 Ab, using a kinase assay with a p38-specific peptide as substrate. In both C3H10T1/2 and C2C12 cells, a significant increase in p38 activity was observed in lysates from cells treated with PeTx compared with those from untreated cells (Fig. 5BGo). In both cell lines maximum p38 activation was measured after 10 min of PeTx treatment, then rapidly declined to reach control levels after 30 min.

To determine whether the ability of PeTx to activate MAPK pathways was dependent upon cAMP and PKA activation, cells were pretreated with H89 (2 µM) before challenge with PeTx. H89 has no effect on ERK1/2 and p38 stimulation by PeTx (Fig. 5Go, C and D). Together these results strongly suggest that PeTx is capable of activating the ERK1/2 and p38 MAPK pathways independently of its ability to inhibit PDEs. Thus, PeTx activates both ERK1/2 and p38, suggesting that some of its effects on osteoblast differentiation may be exerted via the MAPK pathway.

MAPK involvement in PeTx-mediated expression of osteoblast markers
To investigate the involvement of MAPK in PeTx-mediated activation of osteocalcin and Osf2/OC, we specifically blocked each of ERK1/2 and p38 pathways and monitored p147/luc or pOsf2/luc activation in C3H10T1/2 cells challenged with PeTx.

PD98059 and U0126 are synthetic compounds that specifically inhibit the ERK-activating MAPK kinase, MEK1 (22, 23, 24). Both PD98059 (Fig. 6AGo) and U0126 (data not shown) were able to completely block luciferase activation in C3H10T1/2 cells transiently transfected with pmOG2/luc, p147/luc, or pOsf2/luc constructs and stimulated with PeTx. Similar results were obtained in C2C12 cells (data not shown).



View larger version (32K):
[in this window]
[in a new window]
  		Figure 6. MEK-1- and p38-specific inhibitors abolished pentoxifylline-mediated induction of Osf2/Cbfa1 and OC expression. C3H10T1/2 cells were transiently transfected with OC reporter constructs, p147/luc and pmOG2/luc, or Osf2/cbfa1 reporter construct, pOsf2/luc. The culture medium of transfected cells was changed to 2% FCS 18 h after transfection, then preincubated for 1 h with either the MEK-1-specific inhibitor, PD 98059 (A; 30 and 60 µM), or the p38-specific inhibitor, SB203580 (B; 30 and 60 µM), before challenge with PeTx (1.8 mM). After 24-h stimulation, luciferase activity was measured in cell lysates and normalized to the Renilla luciferase signal. Data represent the mean ± SD of a representative experiment. *, P < 0.05, cells treated with PeTx in the presence of PD 98059 or SB203580 compared with PeTx-treated cells in the absence of these inhibitors.

 
SB203580, a bicyclic imidazole compound, is able to selectively inhibit p38 (25). As shown in Fig. 6BGo, C3H10T1/2 cells transiently transfected with p147/luc, pmOG2/luc, or pOsf2/luc construct and pretreated with SB203580 failed to respond to PeTx stimulation. Comparable results were obtained when experiments were repeated using C2C12 cells (data not shown). We also verified that the inhibitors were used at concentrations that efficiently and specifically inhibited their corresponding targets without affecting cell viability (data not shown).

These results demonstrate that MAPK pathways are involved in PeTx-mediated Osf2 activation and osteocalcin stimulation. Given that these pathways also contribute to the BMP-2 signaling events (21), the enhancement of BMP-2 effects on ALP after PeTx treatment may reflect their additional influence on MAPK pathways.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Although some PDE inhibitors have been reported to promote bone formation in vivo, the precise mechanisms leading to these effects are currently unknown. Preliminary studies indicate that PeTx and other PDE inhibitors affect osteoblast differentiation at an early stage, based on the fact that immature cell lines, such as C3H10T1/2 or ST2, but not MC3T3-E1 cells, can respond to PeTx by enhancing the BMP-2-induced ALP activity (26) (our unpublished results). In this study we evaluated the effect of pentoxifylline, a nonselective PDE inhibitor, on osteoblast differentiation using two pluripotent mesenchymal cell lines C3H10T1/2 and C2C12, which acquire the osteoblastic phenotype in the presence of BMP-2, and we examined the respective roles of PKA and MAPK in mediating the effects of PeTx on osteoblast differentiation.

In the two cell lines studied, PeTx was able to induce the expression of the osteoblast marker genes osteocalcin and Osf2/Cbfa1 and to significantly enhance BMP-2-induced ALP gene expression and activity. Although treatment with PeTx alone induced Osf2/Cbfa1 and osteocalcin gene expression, ALP gene expression and activity were positively affected by PeTx only in the presence of BMP-2. Osf2/Cbfa1 is recognized as a master gene in osteoblast differentiation, controlling the expression of several genes expressed in osteoblasts, such as OC, {alpha}1(I) collagen, bone sialoprotein, and osteopontin, which possess OSE2-like elements in their promoters (27). However, the ALP promoter has not been reported to have any OSE2-like element and is most likely not regulated by Osf2/Cbfa1. This may explain why PeTx alone did not affect ALP expression despite its ability to induce Osf2/Cbfa1. Smad proteins are crucial components of TGFß-related signal transduction pathways, and Smad1/5/8 are specifically phosphorylated by BMP receptors (28, 29). Importantly, dominant negative Smads have been reported to block the BMP-2-mediated induction of ALP and osteocalcin in different cell models (18, 30, 31, 32). Here, using a one-hybrid system, we showed that PeTx is able to enhance BMP-2-induced Smad1 transcriptional activity. This suggests that the synergistic effect of BMP-2 and PeTx on ALP gene expression induction might in part be ascribed to an increase in Smad1 transcriptional activity.

Given that inhibition of PDEs leads to an increase in intracellular cAMP levels, triggering the activation of PKA, this signaling pathway might have been responsible for the effect of PeTx or other PDE inhibitors on osteoblast differentiation. PTH, which is capable of increasing bone mineral density in normal and osteopenic bone in humans and animals (33), activates osteocalcin transcription at least in part via PKA activation (34, 35). Our data strongly suggest, however, that the enhancement of osteoblast differentiation after PeTx treatment is independent of PKA activation. Neither treatment with the specific PKA inhibitor, H89, nor the overexpression of PKI, a PKA antagonist, blocked the effects of PeTx on the osteoblast cell lines. Furthermore, and despite the fact that cAMP inducers have been recently shown to inhibit Osf2/Cbfa1 activity in osteoblastic cells (36), PeTx increased both Osf2/Cbfa1 gene expression and the activity of an osteocalcin minimal promoter containing an Osf2/Cbfa1-binding element, OSE2. Together these data strongly suggest that the effects of PeTx on osteoblast differentiation are independent of cAMP increase and/or PKA activation, thus implying that PeTx activates other signaling pathways that positively affect osteoblast differentiation.

It has been suggested that specific PDE4 inhibitors display a potent bone anabolic activity in vivo (37). A recent study clearly showed that in normal mice both PeTx and rolipram, a PDE4-specific inhibitor, increase cortical and cancellous bone mass (11). In preliminary experiments we investigated the effects of specific PDE4, PDE5, and PDE3 inhibitors on osteoblast differentiation. Our data suggest that both PDE3 and PDE4 inhibitors enhance osteoblast differentiation, as assessed by ALP activity and OC and Osf2/Cbfa1 expression (data not shown). Comparable results have been reported by Wakabayashi (38) using the stromal cell line ST-2. Interestingly, osteoblastic differentiation of MC3T3-E1 cells was not affected by any of the PDE-selective inhibitors in the absence or presence of BMP-4 (38), suggesting that these compounds only affect immature cells in which osteoblast commitment is promoted.

Several studies have demonstrated that MAPK cascades play an important role in osteoblast differentiation and function. For example, it has been recently reported that ERK is essential for growth, differentiation, and cell function in human osteoblastic cells (39). MAPK cascades play pivotal roles in the stimulation of osteoblast proliferation by both PTHrP and extracellular calcium-sensing receptor agonists (40, 41). Moreover, activation of MAPKs is involved in the regulation of BMP-2-induced osteoblast differentiation in C2C12 cells (21). Finally, the p38 pathway has been reported to regulate ALP activity in response to activation of Gi protein-coupled receptors (42). Exploring the downstream elements capable of regulating osteoblast gene expression, we have demonstrated that PeTx is able to induce the activation of ERK1/2 and p38 MAPK cascades. We demonstrated that activation of MAPK pathways was independent of cAMP and PKA activation, as treatment of cells with the PKA inhibitor, H89, did not affect the activation of ERK1/2 and p38 by PeTx, and we have shown that forskolin also failed to activate these cascades (data not shown). Moreover, the activation of MAPK signaling pathways was clearly involved in the ability of PeTx to stimulate the expression of the osteoblast differentiation markers, osteocalcin and Osf2/Cbfa1. Actually, treatment of C3H10T1/2 or C2C12 cells with specific inhibitors of ERK and p38 pathways abolished both osteocalcin and Osf2/Cbfa1 induction by PeTx. In this context it is important to note that the ERK1/2 cascade has been very recently implicated in the activation and phosphorylation of the osteoblast-specific factor Osf2/Cbfa1 (43), which binds to the osteoblast-specific element-2, a cis-acting sequence present in the promoter of a series of osteoblast-related genes such as OC, {alpha}1(I) collagen, bone sialoprotein, and osteopontin (27). PDE inhibitors are able to stimulate bone-like nodule formation in rat bone marrow cultures (37), but the role of MAPK in this effect has not been addressed, because general effects on cell proliferation as well as toxic effects after prolonged treatments by MAPK inhibitors complicate the evaluation of their precise roles during mineralization.

The exact mechanism by which PeTx stimulates MAPK pathways remains to be fully elucidated. At present it is unclear whether PeTx directly stimulates the MAPK pathways or whether these are upstream players. For instance, one cannot exclude the possibility that PeTx may target MAPK pathways via a receptor-mediated signal or affect other molecular targets. Theophyllin and SQ 20006, nonselective PDE inhibitors, were shown to inhibit p70S6k activation by a mechanism that is independent of cAMP and cGMP (44). Future studies to better characterize the molecules and pathways involved in PeTx-mediated osteoblast differentiation should contribute to improve our understanding of their anabolic effect on bone.


   Acknowledgments
 


   Footnotes
 
Abbreviations: ALP, Alkaline phosphatase; BMP, bone morphogenetic protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MEK, MAPK kinase; OC, osteocalcin; PeTx, pentoxifylline; PDE, phosphodiesterase.

Received April 23, 2001.

Accepted for publication July 30, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Raisz LG 1997 The osteoporosis revolution. Ann Intern Med 126:458–462[Abstract/Free Full Text]
  2. Stewart AF 1996 PTHrP(1–36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone 19:303–306[Medline]
  3. Jee WS, Ma YF 1997 The in vivo anabolic actions of prostaglandins in bone. Bone 21:297–304[Medline]
  4. Scutt A, Zeschnigk M, Bertram P 1995 PGE2 induces the transition from non-adherent to adherent bone marrow mesenchymal precursor cells via a cAMP/EP2-mediated mechanism. Prostaglandins 49:383–395[CrossRef][Medline]
  5. Whitfield JF, Morley P 1995 Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Trends Pharmacol Sci 16:382–386[CrossRef][Medline]
  6. Whitfield JF, Morley P, Willick GE, Ross V, Barbier JR, Isaacs RJ, Ohannessian-Barry L 1996 Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1–31)NH2 (Ostabolin). Calcif Tissue Int 58:81–87[CrossRef][Medline]
  7. Soderling SH, Beavo JA 2000 Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174–179[CrossRef][Medline]
  8. Beavo JA, Reifsnyder DH 1990 Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150–155[CrossRef][Medline]
  9. Robin JC, Ambrus JL 1984 Study of antiosteoporotic agents in tissue culture. J Med 15:319–322[CrossRef][Medline]
  10. Waki Y, Horita T, Miyamoto K, Ohya K, Kasugai S 1999 Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models. Jpn J Pharmacol 79:477–483[CrossRef][Medline]
  11. Kinoshita T, Kobayashi S, Ebara S, Yoshimura Y, Horiuchi H, Tsutsumimoto T, Wakabayashi S, Takaoka K 2000 Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27:811–817[Medline]
  12. Robin JC, Ambrus JL 1983 Studies on osteoporoses. XI. Effects of a methylxanthine derivative. A preliminary report. J Med 14:137–145[CrossRef][Medline]
  13. Miyamoto K, Waki Y, Horita T, Kasugai S, Ohya K 1997 Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 54:613–617[CrossRef][Medline]
  14. Spinella-Jaegle S, Rawadi G, Kawai S, Gallea S, Faucheu C, Mollat P, Courtois B, Bergaud B, Ramez V, Blanchet A, Adelmant G, Baron R, Roman-Roman S 2001 Sonic hedgehog increases the commitment of pluripotent mesenchymal cells into the osteoblastic lineage and abolishes adipocytic differentiation. J Cell Sci 114:2085–2094[Abstract/Free Full Text]
  15. Ducy P, Karsenty G 1995 Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 15:1858–1869[Abstract]
  16. Aubin JE, Liu F 1996 The osteoblast lineage. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. New York: Academic Press; 51–67
  17. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T 1998 Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273:1872–1879[Abstract/Free Full Text]
  18. Miyazono K 1999 Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 25:91–93[Medline]
  19. Hipskind RA, Bilbe G 1998 MAP kinase signaling cascades and gene expression in osteoblasts. Front Biosci 3:D804–816
  20. Lou J, Tu Y, Li S, Manske PR 2000 Involvement of ERK in BMP-2 induced osteoblastic differentiation of mesenchymal progenitor cell line C3H10T1/2. Biochem Biophys Res Commun 268:757–762[CrossRef][Medline]
  21. Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S 2001 Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 28:491–498[Medline]
  22. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR 1995 PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489–27494[Abstract/Free Full Text]
  23. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686–7689[Abstract/Free Full Text]
  24. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle, PA 1998 Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623–18632[Abstract/Free Full Text]
  25. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. 1994 A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739–746[CrossRef][Medline]
  26. Tsutsumimoto T, Wakabayashi S, Kinoshita T, Horiuchi H, Takaoka K 1999 Pentoxifylline enhances BMP-4-induced differentiation of immature osteoblast lineages. J Bone Miner Res 14(Suppl 1):S354
  27. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747–754[CrossRef][Medline]
  28. Massague J 1996 TGFß signaling: receptors, transducers, and Mad proteins. Cell 85:947–950[CrossRef][Medline]
  29. Massague J 1998 TGF-ß signal transduction. Annu Rev Biochem 67:753–791[CrossRef][Medline]
  30. Yamamoto N, Akiyama S, Katagiri T, Namiki M, Kurokawa T, Suda T 1997 Smad1 and smad5 act downstream of intracellular signalings of BMP-2 that inhibits myogenic differentiation and induces osteoblast differentiation in C2C12 myoblasts. Biochem Biophys Res Commun 238:574–580[CrossRef][Medline]
  31. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T 1998 Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273:1872–1879
  32. Kawai S, Fauchau C, Gallea S, Spinella-Jaegle S, Atfi A, Baron R, Roman-Roman S 2000 Mouse Smad8 phosphorylation downstream of BMP receptors ALK-2, ALK-3 and ALK-6 induces its association with Smad4 and transcriptional activity. Biochem Biophys Res Commun 271:682–687[CrossRef][Medline]
  33. Finkelstein JS 1996 Pharmacological mechanisms of therapeutics: parathyroid hormone. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. New York: Academic Press; 993–1005
  34. Yu XP, Chandrasekhar S 1997 Parathyroid hormone (PTH 1–34) regulation of rat osteocalcin gene transcription. Endocrinology 138:3085–3092[Abstract/Free Full Text]
  35. Boguslawski G, Hale LV, Yu XP, Miles RR, Onyla JE, Santerre RF, Chandrasekhar S 2000 Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase Cdependent pathways. J Biol Chem 275:999–1006[Abstract/Free Full Text]
  36. Tintut Y, Parhami F, Le V, Karsenty G, Demer LL 1999 Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells: ubiquitin/proteasome-dependent regulation. J Biol Chem 274:28875–28879[Abstract/Free Full Text]
  37. Kasugai S, Miyamoto S 1999 Potential of PDE4 inhibitors in the treatment of osteopenia. Drug News Perspect 12:529–534[CrossRef]
  38. Wakabayashi S, Tsutsumimoto T, Kinoshita T, Horiuchi H, Takaoka K 2000 Effect of selective inhibitors for phosphodiesterase on the osteoblastic differentiation of bone marrow-derived stromal cell. J Bone Miner Res 15(Suppl 1):S504
  39. Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Aviolo LV, Cheng SL 2001 Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 276:14443–14450[Abstract/Free Full Text]
  40. Yamaguchi T, Chattopadhyay N, Kifor O, Sanders JL, Brown EM 2000 Activation of p42/44 and p38 mitogen-activated protein kinases by extracellular calcium-sensing receptor agonists induces mitogenic responses in the mouse osteoblastic MC3T3–E1 cell line. Biochem Biophys Res Commun 279:363–368[CrossRef][Medline]
  41. Miao D, Tong XK, Chan G, Panda D, McPherson PS, Goltzman D 2001 PTHrP stimulates osteogenic cell proliferation through protein kinase C-activation of the Ras/mitogen activated protein kinase signaling pathway. J Biol Chem 11:11
  42. Suzuki A, Palmer G, Bonjour JP, Caverzasio J 1999 Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 140:3177–3182[Abstract/Free Full Text]
  43. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT 2000 MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 275:4453–4459
  44. Petritsch C, Woscholski R, Edelmann HML, Ballou LM 1995 Activation of p70 S6 Kinase and Erk-encoded mitogen-activated protein kinases is resistant to high cyclic nucleotide levels in Swiss 3T3 fibroblasts. J Biol Chem 270:26619–26625[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rawadi, G.
Right arrow Articles by Baron, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rawadi, G.
Right arrow Articles by Baron, R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals